Company / Interest Expense
Vivos Therapeutics, Inc. Interest Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$1.4M
FY2025
5-year range
$14.0K / $1.4M
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense changed +9900% YoY in FY2025, a notable deviation from the 3-year average annual change of +3261%.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +59.0%.
Increased from $96,000 to $1M over the past 4 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- +364.2%
- 5-Year CAGR
- +59.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +59.0%, indicating consistent growth.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $14.0K | -85.4% |
| FY2021 | $96.0K | -30.4% |
| FY2020 | $137.9K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026